» Articles » PMID: 32747903

Malignant Phyllodes Tumors of the Breast Associating Malignancy of Both Mesenchymal and Epithelial Components (invasive or in Situ Ductal Carcinoma)

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Phyllodes tumors of the breast are biphasic tumors consisting from an epithelial component and a mesenchymal component. Usually, the mesenchymal component of the tumor is the one who dictates the malignancy of the biphasic proliferation. Presence of the malignancy of the both, epithelial [under the form of invasive carcinoma or ductal carcinoma in situ (DCIS)] and mesenchymal components is very rare. Most of the data available from the literature refers to single case presentations. This paper presents the experience of Prof. Dr. Ion Chiricuţă Oncological Institute (IOCN), Cluj-Napoca, Romania, with the malignant phyllodes tumors with both epithelial and mesenchymal components showing malignancy. Over two decades (1999-2018), four cases of malignant phyllodes tumors with concomitant epithelial and mesenchymal malignancy were found and presented as a case series. Two out of four cases were malignant phyllodes tumors harboring invasive breast carcinomas (one case with associated DCIS and one case of pure invasive carcinoma) and two cases were malignant phyllodes tumors with the epithelial component showing DCIS. Average follow-up period was 67 months (from 39 to 132 months) with a disease-free survival of 58 months.

Citing Articles

Management of Concurrent Malignant Phyllodes Tumor and Invasive Breast Carcinoma.

Chen J, Zhu I, Patel A, Krings G, Chen Y, Yuen F Adv Radiat Oncol. 2024; 9(5):101448.

PMID: 38550370 PMC: 10965428. DOI: 10.1016/j.adro.2024.101448.


A case report of a patient with ductal carcinoma and a malignant phyllodes tumor in situ in 2 separate breasts.

Li C, Zhang C Medicine (Baltimore). 2023; 102(48):e36405.

PMID: 38050272 PMC: 10695601. DOI: 10.1097/MD.0000000000036405.


Unexpectedly High Coexistence Rate of /Invasive Carcinoma In Phyllodes Tumors. 10-Year Retrospective and Review Study.

Gemci O, Altinay S, Ilbar Tartar R, Ferahman S Eur J Breast Health. 2022; 18(4):343-352.

PMID: 36248757 PMC: 9521284. DOI: 10.4274/ejbh.galenos.2022.2022-6-2.


Synchronous Luminal A Ductal Carcinoma In Situ in a Recurrent Benign Phyllodes Tumor Diagnosed Preoperatively: An Unusual Presentation of a Rare Neoplasm.

Brahmachari S, Kumari M, Sharma T, Jagtap M Cureus. 2022; 14(3):e23225.

PMID: 35308191 PMC: 8926381. DOI: 10.7759/cureus.23225.

References
1.
Sugie T, Takeuchi E, Kunishima F, Yotsumoto F, Kono Y . A case of ductal carcinoma with squamous differentiation in malignant phyllodes tumor. Breast Cancer. 2007; 14(3):327-32. DOI: 10.2325/jbcs.14.327. View

2.
Guillot E, Couturaud B, Reyal F, Curnier A, Ravinet J, Lae M . Management of phyllodes breast tumors. Breast J. 2011; 17(2):129-37. DOI: 10.1111/j.1524-4741.2010.01045.x. View

3.
Zeng S, Zhang X, Yang D, Wang X, Ren G . Effects of adjuvant radiotherapy on borderline and malignant phyllodes tumors: A systematic review and meta-analysis. Mol Clin Oncol. 2015; 3(3):663-671. PMC: 4471537. DOI: 10.3892/mco.2015.503. View

4.
Co M, Tse G, Chen C, Wei J, Kwong A . Coexistence of Ductal Carcinoma Within Mammary Phyllodes Tumor: A Review of 557 Cases From a 20-year Region-wide Database in Hong Kong and Southern China. Clin Breast Cancer. 2017; 18(3):e421-e425. DOI: 10.1016/j.clbc.2017.06.001. View

5.
Shin Y, Lee S, Kim K, Park M, Kim J, Yim H . Collision tumor with inflammatory breast carcinoma and malignant phyllodes tumor: a case report and literature review. World J Surg Oncol. 2014; 12:5. PMC: 3895737. DOI: 10.1186/1477-7819-12-5. View